Abbott Laboratories Corporation

Abbott Gmbh & Co Kg

Abbvie Inc.

Abb Vie Deutschland Gmbh & Co. Kg

Other

Abbvie Deutschland Gmbh and Co Kg

Daryl Richard Sauer

Liliane Unger

Wilfried Lubisch

Wilfried Hornberger

Fortuna Haviv

Herve Geneste

Christopher R Dalton

Wilfried Martin Braje

Thorsten K Oost

Wolfgang Wernet

Milan Bruncko

Hervé Geneste

Andreas Haupt

Karla Drescher

John T Randolph

Roland Grandel

Jonathan Greer

Nicholas A Mort

Michele A Kaminski

Lisa Marie Frey

Sean Colm Turner

Helmut Mack

Anil Vasudevan

Vincent L Giranda

Adrian Hobson

Ryan G Keddy

Nicole Teusch

Dominique Bonafoux

Bradley W Crawford

Michael F Jarvis

Thomas Dale Penning

Wilhelm Amberg

Steven Elmore

Michael D Wendt

Aaron R Kunzer

Todd Warren Rockway

Mario Mezler

Bernhard K Mueller

Michael F Bradley

Jianchun Gong

Sheela A Thomas

Kathy A Sarris

Margaretha Henrica Maria Bakker

Philip J Hajduk

Moshe Weitzberg

Charles J Nichols

Andrea Hager-Wernet, Legal Representative

Vicki L Nienaber

Steven Lewis Swann, Jr

Chaohong Sun

Steve Swann, Jr

Willian J McClellan

Philip Waid

Bernhard K Muller

William J Mcclellan

Margaretha Henrica Bakker

Kathy Sarris

Bernhard K MÜLLER

Ryan Keddy

Adrian Donald Hobson

The present invention relates to novel 1,3-dihydroindol-2-one (oxindole) derivatives of the formula (I) in which

Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them

The present invention relates to heterocyclic compounds which are positive modulators of metabotropic glutamate receptor. The present invention also relates to the use of these compounds for preparing a pharmaceutical composition and to a method of treating a medical disorder, selected from neurological and psychiatric disorders associated with glutamate dysfunction.

Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor)

The present invention relates to novel 4-(4-pyridyl)-benzamides of the formula (I). The compounds I possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of Rho kinases (ROCKs). Rand Rare, independently of each other, hydrogen, hydroxy, cyano, C-C-alkyl, C-C-haloalkyl, C-C-alkoxy or C-C-haloalkoxy; R, R, Rand Rare, independently of each other, hydrogen, hydroxy, halogen, cyano, C-C-alkyl, C-C-haloalkyl, C-C-alkoxy, C-C-haloalkoxy, amino, C-C-alkylamino or di-(C-C-alkyl)-amino; Ris hydrogen, C-C-alkyl, C-C-haloalkyl, aryl or aryl-C-C-alkyl; Ris a group of the formula &#x2014;X&#x2014;W, where X is a single bond, C-C-alkylene or C-C-alkylene-O&#x2014;, where the alkylene group in the three last-mentioned radicals may be linear or branched and may be partly or fully halogenated and/or may be substituted by a hydroxyl group and/or may be interrupted by an oxygen atom; and W is a cyclic radical selected from phenyl and a 5- or 6-membered saturated, partly unsaturated or aromatic heterocyclic ring which contains as ring members 1, 2 or 3 heteroatoms selected from O, S and N and optionally 1 or 2 carbonyl groups; Ris a group of the formula &#x2014;Y&#x2014;Z, where Z is hydrogen, halogen, OR, NRR, S(O)&#x2014;R, phenyl which may carry 1, 2, 3 or 4 substituents Ror a 5- or 6-membered saturated, partly unsaturated or aromatic heterocyclic ring; and Y is linear or branched CC-alkylene which may be partly or fully halogenated and/or may be substituted by a hydroxyl group and/or a phenyl ring; or, in case Z is phenyl or the 5- or 6-membered heterocyclic ring as defined above, Y can also be a single bond. 

4-(4-pyridinyl)-benzamides and their use as rock activity modulators

The present invention relates to novel 1,3-dihydroindol-2-one (oxindole) derivatives of the formula (I) in which A, R, R, R, R, and Rare defined according to claim 1, and to medicaments containing them for the treatment of diseases. In particular, the novel oxindole derivatives can be used for the control and/or prophylaxis of various vasopressin-dependent or oxytocin-dependent diseases.

The invention related to N-[(piperazinyl)hetaryl]arylsulfonamide compounds of the general formula (I) in which Q is a bivalent, 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents Rwhich is/are selected, independently of each other, from halogen, CN, NO, COR, COR, C-C-alkyl and C-C-haloalkyl; Ar is phenyl or a 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents R, which is/are selected from halogen, NO, CN, COR, COR, C-C-alkyl, C-C-alkenyl, C-C-alkynyl, C-C-cycloalkyl, C-C-cycloalkyl-C-C-alkyl and C-C-haloalkyl, with it also being possible for two radicals Rwhich are bonded to adjacent C atoms of Ar to be together C-C-alkylene; Ris hydrogen, C-C-alkyl, C-C-haloalkyl, C-C-cycloalkyl, C-C-cycloalkyl-C-C-alkyl, C-C-hydroxyalkyl, C-C-alkoxy-C-C-alkyl, C-C-alkenyl or C-C-alkynyl; with the radicals n, R, R, R, Rand Rhaving the meanings given in the patent claims, to the N-oxides and to the physiologically tolerated acid addition salts of these compounds and to pharmaceutical compositions which comprise at least one N-[(piperazinyl)hetaryl]arylsulfonamide compound as claimed in one of claimstoand/or at least one physiologically tolerated acid addition salt of I and/or an N-oxide of I, where appropriate together with physiologically acceptable carriers and/or auxiliary substances for treating diseases which respond to influencing by dopamine Dreceptor antagonists or agonists, in particular for treating diseases of the central nervous system and disturbances of kidney function. 

N-[piperazinyl hetaryl]arylsufonamide compounds with affinity for the dopamine D3 receptor

The present invention relates to novel 1,3-dihydroindol-2-one (oxindole) derivatives of the formula (I) in which A, R, R, R, R, and Rare defined according to claim, and to medicaments containing them for the treatment of diseases. In particular, the novel oxindole derivatives can be used for the control and/or prophylaxis of various vasopressin-dependent or oxytocin-dependent diseases.

The invention relates to tetrahydrobenzazepines of the general formula I in which the variables Ar, A, B, Y, Rand Rhave the meanings indicated in claim, as well as the N-oxides of these compounds, the physiologically tolerated acid addition salts of these compounds and the physiologically tolerated acid addition salts of the N-oxides. The invention also relates to a pharmaceutical composition that comprises at least one tetrahydrobenzazepine compound of the formula I, the physically tolerated acid addition salt of I, the N-oxide of compound of the formula I and/or the physically tolerated acid addition salts of the N-oxides of I, and further to the use of a compound according to the present invention for treating disorders that respond beneficially to dopamine Dreceptor antagonists or dopamine Dagonists. The compounds according to the invention are preferably useful for the treatment of disorders of the central nervous system such as schizophrenia and depression and for the treatment of renal function disorders.

[object Object]

The present invention relates to 1H-benzimidazole-4-carboxamides of formula (I), their preparation, and their use as inhibitors of the enzyme poly(ADP-ribose)polymerase for the preparation of drugs.

Potent PARP inhibitors

The invention relates to substituted N-heterocyclic compounds of general formula (I.A) and to the tautomers of the compounds the physiologically acceptable salts of the compounds and the physiologically acceptable salts of the tautomers of the compounds. The invention also relates to the use of these compounds and their pharmacologically acceptable salts in the production of a pharmaceutical agent for treating diseases that respond to the influence exerted by dopamine Dreceptor ligands, especially for treating diseases of the central nervous system, especially schizophrenia and/or depression.

Compounds that inhibit survivin, compositions containing the compounds and methods of treating diseases in which survivin is unregulated or overexpressed are disclosed.

Survivin inhibitors

The present invention relates to novel 1,3-dihydroindol-2-one (oxindole) derivatives of the formula (I) in which A, R, R, RRand Rare defined according to claim 1, and to medicaments containing them for the treatment of diseases. In particular, the novel oxindole derivatives can be used for the control and/or prophylaxis of various vasopressin-dependent or oxytocin-dependent diseases. 

Compounds having the formula are angiogenesis inhibitors. Also disclosed are compositions containing the compounds, methods of making the compounds, and methods of treatment using the compounds.

Ureas having antiangiogenic activity

The invention relates to N-[(piperazinyl)hetaryl]arylsulfonamide compounds of the general formula I in which

N-[(piperazinyl)hetaryl]arylsulfonamide compounds

Naphthamidine urokinase inhibitors

Growing community of inventors

Trevor, WI, United States of America

Daryl Richard Sauer